Danae Alexandrou, Veronica Drozdowski-Nuccio, Kayeromi Gomez, Steven Charous
{"title":"诊断为咽外恶性肿瘤和声带麻痹患者的预期寿命。","authors":"Danae Alexandrou, Veronica Drozdowski-Nuccio, Kayeromi Gomez, Steven Charous","doi":"10.1177/01455613251360134","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To determine whether the presence of vocal cord paralysis (VCP) has an impact on overall survival (OS) and quality of life in patients diagnosed with extralaryngeal malignancies.</p><p><strong>Methods: </strong>This was a retrospective chart review of patients at a quaternary medical center from 2007 to 2022. Information on demographics, cancer diagnosis, treatment, and intervention for VCP was collected. Patients were identified using <i>International Classification of Diseases</i> (ICD)-9 and ICD-10 codes for various malignancies and VCP and cross-referenced. Patients with both VCP and extralaryngeal malignancy were included, while those without malignancy, with laryngeal cancer, VCP unrelated to cancer, or without laryngoscopy-confirmed VCP were excluded. No validated instruments to measure quality of life were utilized.</p><p><strong>Results: </strong>A total of 346 patients with VCP related to 52 distinct, extralaryngeal malignancies were identified. Mean OS was 97.35 months. Mean OS for those diagnosed with early (stage 1 or 2) cancers was 101.48 months and 79.88 months for late (stage 3 or 4) cancers (<i>P</i> = <.0001). Many of our patients (56.6%) did not receive VCP treatment.</p><p><strong>Conclusion: </strong>Treatment for cancer patients with VCP poses a unique challenge with a multitude of factors affecting management. However, given that patients survive months after VCP diagnosis, they should be offered treatments that carry low morbidity and increase their quality of life.</p>","PeriodicalId":93984,"journal":{"name":"Ear, nose, & throat journal","volume":" ","pages":"1455613251360134"},"PeriodicalIF":0.7000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Life Expectancy in Patients Diagnosed with Extralaryngeal Malignancies and Vocal Cord Paralysis.\",\"authors\":\"Danae Alexandrou, Veronica Drozdowski-Nuccio, Kayeromi Gomez, Steven Charous\",\"doi\":\"10.1177/01455613251360134\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To determine whether the presence of vocal cord paralysis (VCP) has an impact on overall survival (OS) and quality of life in patients diagnosed with extralaryngeal malignancies.</p><p><strong>Methods: </strong>This was a retrospective chart review of patients at a quaternary medical center from 2007 to 2022. Information on demographics, cancer diagnosis, treatment, and intervention for VCP was collected. Patients were identified using <i>International Classification of Diseases</i> (ICD)-9 and ICD-10 codes for various malignancies and VCP and cross-referenced. Patients with both VCP and extralaryngeal malignancy were included, while those without malignancy, with laryngeal cancer, VCP unrelated to cancer, or without laryngoscopy-confirmed VCP were excluded. No validated instruments to measure quality of life were utilized.</p><p><strong>Results: </strong>A total of 346 patients with VCP related to 52 distinct, extralaryngeal malignancies were identified. Mean OS was 97.35 months. Mean OS for those diagnosed with early (stage 1 or 2) cancers was 101.48 months and 79.88 months for late (stage 3 or 4) cancers (<i>P</i> = <.0001). Many of our patients (56.6%) did not receive VCP treatment.</p><p><strong>Conclusion: </strong>Treatment for cancer patients with VCP poses a unique challenge with a multitude of factors affecting management. However, given that patients survive months after VCP diagnosis, they should be offered treatments that carry low morbidity and increase their quality of life.</p>\",\"PeriodicalId\":93984,\"journal\":{\"name\":\"Ear, nose, & throat journal\",\"volume\":\" \",\"pages\":\"1455613251360134\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ear, nose, & throat journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/01455613251360134\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ear, nose, & throat journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/01455613251360134","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Life Expectancy in Patients Diagnosed with Extralaryngeal Malignancies and Vocal Cord Paralysis.
Objective: To determine whether the presence of vocal cord paralysis (VCP) has an impact on overall survival (OS) and quality of life in patients diagnosed with extralaryngeal malignancies.
Methods: This was a retrospective chart review of patients at a quaternary medical center from 2007 to 2022. Information on demographics, cancer diagnosis, treatment, and intervention for VCP was collected. Patients were identified using International Classification of Diseases (ICD)-9 and ICD-10 codes for various malignancies and VCP and cross-referenced. Patients with both VCP and extralaryngeal malignancy were included, while those without malignancy, with laryngeal cancer, VCP unrelated to cancer, or without laryngoscopy-confirmed VCP were excluded. No validated instruments to measure quality of life were utilized.
Results: A total of 346 patients with VCP related to 52 distinct, extralaryngeal malignancies were identified. Mean OS was 97.35 months. Mean OS for those diagnosed with early (stage 1 or 2) cancers was 101.48 months and 79.88 months for late (stage 3 or 4) cancers (P = <.0001). Many of our patients (56.6%) did not receive VCP treatment.
Conclusion: Treatment for cancer patients with VCP poses a unique challenge with a multitude of factors affecting management. However, given that patients survive months after VCP diagnosis, they should be offered treatments that carry low morbidity and increase their quality of life.